IMCD (OTCMKTS:IMCDY – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 1,389 shares, a growth of 481.2% from the September 30th total of 239 shares. Based on an average daily volume of 17,776 shares, the short-interest ratio is currently 0.1 days.
IMCD Stock Down 0.9%
OTCMKTS:IMCDY opened at $55.95 on Tuesday. IMCD has a fifty-two week low of $39.76 and a fifty-two week high of $61.56. The stock’s 50-day moving average is $55.83 and its two-hundred day moving average is $51.71.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on IMCDY. UBS Group raised shares of IMCD to a “buy” rating in a research note on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IMCD in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.
About IMCD
IMCD N.V. is a global distributor and formulator of specialty chemicals and food and pharmaceutical ingredients. The company connects manufacturers with customers across a range of industries, including coatings and construction, personal care, pharmaceuticals, food and nutrition, lubricants, advanced materials, and industrial solutions.
In addition to distributing products, IMCD provides technical support, application development, formulation assistance, regulatory guidance, and supply-chain services.
Featured Articles
- Five stocks we like better than IMCD
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for IMCD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMCD and related companies with MarketBeat.com's FREE daily email newsletter.
